UK-based biotechnology firm PsiOxus Therapeutics has initiated a clinical trial with NG-641, a four transgene tumour-microenvironment modifying gene therapy, to treat cancer patients.

For the first time, a tumour-specific virus comprising four unique therapeutic transgenes is being administered to subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PsiOxus chief scientific officer Dr Brian Champion said: “With NG-641, our approach of systemically delivering gene therapy vectors to turn tumour cells into drug factories is being deployed to deliver a bispecific T-cell activating protein to target cancer-associated fibroblasts (CAFs) via the fibroblast activation protein (FAP).

“This mechanism allows us to target one of the most important immunosuppressive cells in the tumour microenvironment.”

Besides the FAP-targeted T-cell activator, the cancer gene therapy delivers three other molecules to additionally recruit and activate T-cells in order to induce an anti-tumour immune response (IR).

NG-641 is, therefore, the first four transgene viral gene therapy treatments for the study of cancer in patients.

PsiOxus chief medical officer Dr Tom Lillie added: “I look forward to the opportunity to work with the rest of the PsiOxus team as we continue to develop innovative gene therapy products to treat and benefit cancer patients.”

The company noted that the Phase I STAR study is being conducted at multiple cancer centres in the US. It will assess the safety and efficacy of NG-641 in patients with solid tumours.

PsiOxus’ proprietary gene therapy platform, T-SIGn, is based on the company’s oncolytic virus enadenotucirev and delivers different combinations of therapeutic transgenes to carcinomas.

In March 2016, PsiOxus began the Octave trial of paclitaxel combined with the oncolytic virotherapy enadenotucirev to treat patients with ovarian cancer.